CLSDQ (Clearside Biomedical) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 06, 2026)


CLSDQ Clearside Biomedical Inc CLSDQ
49 GF Score
Price $0.13
GF Value $6.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Clearside Biomedical's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

CLSDQ vs LYRA, EVFM, ATXI: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Clearside Biomedical's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearside Biomedical Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Margin of Safety % (DCF FCF Based) falls into.


CLSDQ
49GF Score
Clearside Biomedical Inc CLSDQ
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clearside Biomedical (CLSDQ) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34. GuruFocus considers Clearside Biomedical to be Possible Value Trap.

Key valuation signals for CLSDQ:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clearside Biomedical Business Description

Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for CLSDQ

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$6.34
GF Value